Floatz logo

AK105

MSI-H or dMMR Advanced Solid Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.monoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the MSI-H or dMMR Advanced Solid Tumors cohort.

Asset / SponsorPhaseRating
Catequentinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2CCC
eik1005
Eikon Therapeutics
Phase 1/2CCC
Pembrolizumab
Eikon Therapeutics
Phase 1/2CCC
qls1317
Shanghai Qilu Pharmaceutical Research and Development Center LTD
Phase 1NR

Same molecule, other indications

AK105 is also rated in:

hepatocellular carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
squamous cell lung carcinomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →